Estimating the Size of the Hidden Population of COVID-19


Дәйексөз келтіру

Толық мәтін

Аннотация

Introduction:An asymptomatic population has the same infection as symptomatic individuals, so these individuals can unknowingly spread the virus. It is not possible to predict the rate of epidemic growth by considering only the identified isolated or hospitalized population. In this study, we want to estimate the size of the COVID-19 population, based on information derived from patients visiting medical centers. So, individuals who do not receive a formal diagnosis in those medical centers can be considered as hidden.

Methodology:To estimate the Bayesian size of the hidden population of COVID-19 a respondentdriven sampling (RDS) method was used. Twenty-three people infected with COVID-19 seeds and who had positive PCR test results were selected as seeds. These participants were asked whether any of their friends and acquaintances who had COVID-19 did not visit a medical center or hid their illness. Access to other patients was gained through friendship and kinship, hence allowing the sampling process to proceed.

Results:Out of 23 selected seeds, only 15 seeds remained in the sample and the rest were excluded due to not participating in the further sampling process. After 5 waves, 50 people with COVID-19 who had hidden their disease and were not registered in the official statistics were included in the sample. It was estimated that 12,198 people were infected with COVID-19 in Khalkhal city in 2022. This estimate was much higher than recorded in the official COVID-19 statistics.

Conclusions:The study findings indicate that the estimated 'true' numbers of COVID-19 patients in one town in Iran were significantly higher compared to the official numbers. The RDS method can help capture the potential size of infections in further pandemics or outbreaks globally.

Авторлар туралы

Esmaeil Mehraeen

Department of Health Information Technology, Khalkhal University of Medical Sciences

Email: info@benthamscience.net

Fatemeh Akhtaran

Faculty of Mathematical Sciences, Shahid Beheshti University

Email: info@benthamscience.net

Mohammad Faridrohani

Faculty of Mathematical Sciences, Shahid Beheshti University

Email: info@benthamscience.net

Arian Afzalian

School of medicine, Tehran University of Medical Sciences

Email: info@benthamscience.net

Hengameh Mojdeganlou

Department of Pathology, The Johns Hopkins University, School of Medicine

Email: info@benthamscience.net

Zeinab Ghanbari

Student Research Committee, Khalkhal University of medical science

Email: info@benthamscience.net

Yasamin Fathzadeh

Student Research Committee, Khalkhal University of medical sciences

Email: info@benthamscience.net

Mohadeseh Gholizadeh

Student Research Committee, Khalkhal University of medical sciences

Email: info@benthamscience.net

SeyedAhmad SeyedAlinaghi

Iranian Research Center for HIV/AIDS, Iranian Institute for Reduction of High-Risk Behaviors, Tehran University of Medical Science

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Daniel Hackett

Physical Activity, Lifestyle, Ageing and Wellbeing Faculty Research Group, School of Health Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney

Email: info@benthamscience.net

Әдебиет тізімі

  1. SeyedAlinaghi S, Karimi A, MohsseniPour M, et al. The clinical outcomes of COVID-19 in HIV-positive patients: A systematic review of current evidence. Immun Inflamm Dis 2021; 9(4): 1160-85. doi: 10.1002/iid3.497 PMID: 34324280
  2. Dadras O, SeyedAlinaghi S, Karimi A, et al. COVID-19 mortality and its predictors in the elderly: A systematic review. Health Sci Rep 2022; 5(3): e657.
  3. SeyedAlinaghi S, Karimi A, Mojdeganlou H, et al. Impact of COVID-19 pandemic on routine vaccination coverage of children and adolescents: A systematic review. Health Sci Rep 2022; 5(2): e00516. PMID: 35224217
  4. Oliaei S, SeyedAlinaghi S, Mehrtak M, et al. The effects of hyperbaric oxygen therapy (HBOT) on coronavirus disease-2019 (COVID-19): A systematic review. Eur J Med Res 2021; 26(1): 96.
  5. Nishiura H, Kobayashi T, Miyama T, et al. Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19). Int J Infect Dis 2020; 94: 154-5. doi: 10.1016/j.ijid.2020.03.020 PMID: 32179137
  6. Tuite AR, Ng V, Rees E, Fisman D. Estimation of COVID-19 outbreak size in Italy. Lancet Infect Dis 2020; 20(5): 537.
  7. Böhning D, Rocchetti I, Maruotti A, Holling H. Estimating the undetected infections in the Covid-19 outbreak by harnessing capture-recapture methods. Int J Infect Dis 2020; 97: 197-201. doi: 10.1016/j.ijid.2020.06.009 PMID: 32534143
  8. Ocagli H, Azzolina D, Lorenzoni G, et al. Using social networks to estimate the number of COVID-19 Cases: The incident (hidden COVID-19 cases network estimation) study protocol. Int J Environ Res Public Health 2021; 18(11): 5713. doi: 10.3390/ijerph18115713 PMID: 34073448
  9. Comiskey CM, Snel A, Banka PS. First back-calculation and infection fatality multiplier estimate of the hidden prevalence of COVID-19 in Ireland. Eur J Public Health 2021; 31(4): 908-12. doi: 10.1093/eurpub/ckab126 PMID: 34245277
  10. Vaid S, Cakan C, Bhandari M. Using machine learning to estimate unobserved COVID-19 infections in North America. J Bone Joint Surg Am 2020; 102(13): e70. doi: 10.2106/JBJS.20.00715 PMID: 32618918
  11. Barrie MB, Lakoh S, Kelly JD, et al. SARS-CoV-2 antibody prevalence in Sierra Leone. medRxiv 2021.
  12. Salganik MJ, Heckathorn DD. 5. Sampling and estimation in hidden populations using respondent-driven sampling. Sociol Methodol 2004; 34(1): 193-240. doi: 10.1111/j.0081-1750.2004.00152.x
  13. Handcock MS, Gile KJ, Mar CM. Estimating hidden population size using respondent-driven sampling data. Electron J Stat 2014; 8(1): 1491-521. doi: 10.1214/14-EJS923 PMID: 26180577
  14. Gile KJ. Improved inference for respondent-driven sampling data with application to HIV prevalence estimation. J Am Stat Assoc 2011; 106(493): 135-46. doi: 10.1198/jasa.2011.ap09475
  15. West M. Inference in successive sampling discovery models. J Econom 1996; 75(1): 217-38. doi: 10.1016/0304-4076(95)01777-1
  16. Abadie R, Habecker P, Carrasco KG, et al. Employing respondent driven sampling (RDS) to recruit people who inject drugs (PWID) and other hard-to-reach populations during COVID-19: Lessons learned. Front Psychiatry 2022; 13: 990055. doi: 10.3389/fpsyt.2022.990055 PMID: 36262631
  17. Abadie R, Welch-Lazoritz M, Bilal K, Dombrowski K. Social determinants of HIV/HCV co-infection: A case study from people who inject drugs in rural Puerto Rico. Addict Behav Rep 2017; 5: 29-32. doi: 10.1016/j.abrep.2017.01.004 PMID: 28983502
  18. Lee S, Ong AR, Elliott M. Exploring mechanisms of recruitment and recruitment cooperation in respondent driven sampling. J Off Stat 2020; 36(2): 339-60. doi: 10.2478/jos-2020-0018 PMID: 33162642
  19. Wylie JL, Jolly AM. Understanding recruitment: outcomes associated with alternate methods for seed selection in respondent driven sampling. BMC Med Res Methodol 2013; 13(1): 93. doi: 10.1186/1471-2288-13-93 PMID: 23865487
  20. Kazerooni PA, Motazedian N, Motamedifar M, et al. The prevalence of human immunodeficiency virus and sexually transmitted infections among female sex workers in Shiraz, South of Iran: By respondent-driven sampling. Int J STD AIDS 2014; 25(2): 155-61. doi: 10.1177/0956462413496227 PMID: 23970644
  21. Wickersham JA, Gibson BA, Bazazi AR, et al. Prevalence of human immunodeficiency virus and sexually transmitted infections among cisgender and transgender women sex workers in greater Kuala Lumpur, Malaysia: Results from a respondent-driven sampling study. Sex Transm Dis 2017; 44(11): 663-70. doi: 10.1097/OLQ.0000000000000662 PMID: 28708696
  22. Oliveira MP, Matos MAD, Silva ÁMC, et al. Prevalence, risk behaviors, and virological characteristics of hepatitis B virus infection in a group of men who have sex with men in Brazil: Results from a respondent-driven sampling survey. PLoS One 2016; 11(8): e0160916. doi: 10.1371/journal.pone.0160916 PMID: 27508385
  23. Solomon SS, McFall AM, Lucas GM, et al. Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis. PLoS Med 2017; 14(11): e1002460. doi: 10.1371/journal.pmed.1002460 PMID: 29182638
  24. Khamsiriwatchara A, Wangroongsarb P, Thwing J, et al. Respondent-driven sampling on the Thailand-Cambodia border. I. Can malaria cases be contained in mobile migrant workers? Malar J 2011; 10(1): 120. doi: 10.1186/1475-2875-10-120 PMID: 21554744
  25. Mukherjee M, Maity C, Chatterjee S. Media use pattern as an indicator of mental health in the COVID-19 pandemic: Dataset from India. Data Brief 2021; 34: 106722. doi: 10.1016/j.dib.2021.106722 PMID: 33490336
  26. Johnson CA, Tran DN, Mwangi A, et al. Incorporating respondent-driven sampling into web-based discrete choice experiments: Preferences for COVID-19 mitigation measures. Health Serv Outcomes Res Methodol 2022; 22(3): 297-316. doi: 10.1007/s10742-021-00266-4 PMID: 35035272
  27. Helms YB, Hamdiui N, Kretzschmar MEE, et al. Applications and recruitment performance of web-based respondent-driven sampling: Scoping review. J Med Internet Res 2021; 23(1): e17564. doi: 10.2196/17564 PMID: 33448935
  28. Rocchetti I, Böhning D, Holling H, Maruotti A. Estimating the size of undetected cases of the COVID-19 outbreak in Europe: An upper bound estimator. Epidemiol Methods 2020; 9(s1): 20200024. doi: 10.1515/em-2020-0024
  29. Rippinger C, Bicher M, Urach C, et al. Evaluation of undetected cases during the COVID-19 epidemic in Austria. BMC Infect Dis 2021; 21(1): 70. doi: 10.1186/s12879-020-05737-6 PMID: 33441091
  30. Mehraeen E, Pashaei Z, Akhtaran FK, et al. Estimating methods of the undetected infections in the COVID-19 outbreak: A systematic review. Infect Disord Drug Targets 2023; 23(4): e240123213106. doi: 10.2174/1871526523666230124162103 PMID: 36698234
  31. Mehraeen E, Dadras O, Afsahi AM, et al. Vaccines for COVID-19: A systematic review of feasibility and effectiveness. Infect Disord Drug Targets 2022; 22(2): e230921196758. doi: 10.2174/1871526521666210923144837 PMID: 34554905
  32. Mehraeen E, Najafi Z, Hayati B, et al. Current treatments and therapeutic options for COVID-19 patients: A systematic review. Infect Disord Drug Targets 2022; 22(1): e260721194968. doi: 10.2174/1871526521666210726150435 PMID: 34313204
  33. Mehraeen E, Salehi MA, Behnezhad F, Moghaddam HR. SeyedAlinaghi S. Transmission modes of COVID-19: A systematic review. Infect Disord Drug Targets 2021; 21(6): e170721187995. doi: 10.2174/1871526520666201116095934 PMID: 33200716

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024